Prot #VX17-445-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)

Project: Research project

Project Details

StatusFinished
Effective start/end date7/10/18 → 8/31/23

Funding

  • Greenphire, Inc. ((OE) Prot #VX17-445-103 // (OE) Prot #VX17-445-103)
  • Vertex Pharmaceuticals Incorporated ((OE) Prot #VX17-445-103 // (OE) Prot #VX17-445-103)